Browsing Tag
Eli Lilly and Company
140 posts
Eli Lilly lifts 2025 outlook after Zepbound and Mounjaro drive 38% Q2 revenue surge
Eli Lilly’s Q2 2025 revenue jumped 38% to $15.56 billion, led by Zepbound and Mounjaro. Read how product growth is reshaping guidance.
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.
Lilly to expand into cardiovascular gene editing with Verve Therapeutics acquisition
Eli Lilly’s $1.3B acquisition of Verve Therapeutics targets breakthrough one-time gene therapies for high-risk cardiovascular patients. Read more.
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
The race for non-opioid pain relief: who’s leading the post-opioid era?
Explore the top companies and mechanisms leading the post-opioid pain relief revolution in 2025. Who's winning the race for safe, effective chronic pain drugs?
How Eli Lilly’s $1bn SiteOne deal strengthens its bid to lead in non-opioid pain therapies
Eli Lilly to acquire SiteOne Therapeutics for up to $1B, betting on STC-004 to redefine non-opioid pain treatment. Read why investors and analysts are watching.
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.
Eli Lilly strengthens ties with Purdue University to advance AI-powered drug discovery
Eli Lilly expands Purdue partnership with a $250M investment to drive AI-powered drug discovery, R&D scalability, and long-term pharma innovation.
Zepbound outperforms Wegovy in SURMOUNT-5 trial: Eli Lilly’s weight-loss drug achieves 47% greater relative reduction
Zepbound outperforms Wegovy with 20.2% weight loss in SURMOUNT-5 trial. See how Eli Lilly’s stock and investor sentiment responded to this clinical milestone.
Wall Street rout: Top U.S. stock losers on May 1 reflect deep-sector woes, policy shocks, and earnings misses
Discover how major U.S. companies like Eli Lilly and Becton Dickinson are navigating stock declines amid economic and industry challenges.